Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...